The soft tissue sarcoma market across the 7MM is growing driven by increasing disease recognition, improved diagnostic practices, and growing research activity supporting the development of novel therapeutic approaches, including TBI-1301 (mipetresgene autoleucel) (Takara Bio), INT230-6 (Intensity Therapeutics), ZEPZELCA (lurbinectedin) (PharmaMar/Jazz Pharmaceuticals), Pegargiminase (Polaris), and others.

LAS VEGAS, July 15, 2026 /PRNewswire/ — Recently published Soft Tissue Sarcoma Market Insights report by DelveInsight includes a comprehensive understanding of current treatment practices, soft tissue sarcoma emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. 

Soft Tissue Sarcoma Market Summary

• The market size for soft tissue sarcoma was found to be USD 310 million in the 7MM in 2025.
• The United States accounted for the largest soft tissue sarcoma treatment market size, approximately 85% of the total market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• In 2025, the 7MM recorded approximately 40,000 new STS cases, with incidence expected to gradually rise through 2036, reflecting the persistent clinical burden and ongoing need for more effective treatment options across diverse STS subtypes.
• Leading soft tissue sarcoma companies, such as Takara Bio, Intensity Therapeutics, PharmaMar, Jazz Pharmaceuticals, Polaris, Advenchen Laboratories, Philogen, Sun Pharma, Eli Lilly, Replimune, Immutep, US WorldMeds, GSK, QBiotics Group, and others, are developing new soft tissue sarcoma treatment drugs that can be available in the soft tissue sarcoma market in the coming years. 
• The promising soft tissue sarcoma therapies in clinical trials include TBI-1301 (mipetresgene autoleucel), INT230-6, ZEPZELCA (lurbinectedin), Pegargiminase, Catequentinib Hydrochloride (AL3818), Fibromun, Abemaciclib (VERZENIO), Vusolimogene Oderparepvec (RP1) + Nivolumab, Pembrolizumab (KEYTRUDA) + Eftilagimod Alpha, Letetresgene autoleucel, Risvutatug rezetecan, Tigilanol Tiglate, and others.

Discover what is the future of the soft tissue sarcoma treatment market @ https://www.delveinsight.com/report-store/soft-tissue-sarcoma-market

Key Factors Driving the Growth of the Soft Tissue Sarcoma Market 

• Rising Incidence of Soft Tissue Sarcoma: The increasing number of diagnosed soft tissue sarcoma cases worldwide is expanding the patient pool requiring treatment. Improved disease awareness, aging populations, and enhanced diagnostic capabilities are contributing to higher diagnosis rates, driving demand for effective therapies.
• Advancements in Precision Medicine and Biomarker-Based Therapies: Growing understanding of the molecular and genetic heterogeneity of STS has accelerated the development of precision medicine approaches. Biomarker-driven therapies and molecular profiling are enabling more personalized treatment strategies, improving clinical outcomes, and supporting STS market growth.
• Advances in Soft Tissue Sarcoma Biology: Improved understanding of STS biology, including fusion-driven sarcomas, CDK4/MDM2-amplified liposarcoma, and angiogenic signaling, has strengthened the rationale for therapeutic development beyond cytotoxic chemotherapy.
• Robust Pipeline of Novel Therapeutics: The STS treatment pipeline includes emerging therapies such as TBI-1301 (mipetresgene autoleucel) (Takara Bio), INT230-6 (Intensity Therapeutics), ZEPZELCA (lurbinectedin) (PharmaMar/Jazz Pharmaceuticals), Pegargiminase (Polaris), Catequentinib Hydrochloride (AL3818) (Advenchen Laboratories), and other novel cell therapies, intratumoral agents, and targeted approaches under clinical evaluation.

Download the report to understand the top emerging therapies in soft tissue sarcoma @ Soft Tissue Sarcoma Clinical Trials

According to Ramandeep Singh, senior consultant of forecasting at DelveInsight, the future landscape appears promising, with ongoing development of innovative therapies such as lurbinectedin (ZEPZELCA), which is anticipated to enter the US market in 2028. The therapy is expected to generate notable revenue at launch, with growth projected through 2036, driven by fast uptake in eligible patient populations.

Soft Tissue Sarcoma Market Analysis

• The soft tissue sarcoma therapeutic landscape is evolving rapidly, with a combination of established treatments and a robust pipeline addressing localized, advanced, metastatic, and recurrent disease across diverse histological subtypes. 
• Current and investigational therapies are designed to suppress tumor growth, inhibit angiogenesis, overcome immune escape mechanisms, and target molecular pathways involved in sarcoma progression. 
• While chemotherapy, targeted therapies, and tyrosine kinase inhibitors remain the foundation of treatment, innovative modalities such as engineered T-cell therapies, immune checkpoint inhibitors, and precision medicine approaches are broadening therapeutic possibilities. 
• Together, these developments underscore continued efforts to address significant unmet clinical needs while tackling the biological heterogeneity of STS across the 7MM.
• Small-molecule therapies continue to represent a cornerstone of STS management by selectively targeting oncogenic signaling pathways, tumor proliferation, and angiogenesis. 
• Approved agents such as Crizotinib (XALKORI) and Trabectedin (YONDELIS) remain integral treatment options for specific STS subtypes, while investigational candidates including INT230-6 and lurbinectedin (ZEPZELCA) are advancing the next generation of targeted therapies. 
• These emerging agents are focused on strengthening antitumor efficacy, prolonging disease control, and expanding therapeutic options for patients with advanced or metastatic disease, reinforcing the growing importance of small molecules within the STS treatment paradigm.
• Gene and cell therapies are emerging as transformative approaches in STS, leveraging engineered immune cells to recognize and eliminate tumor-specific targets. 
• Pipeline candidates such as TBI-1301 (mipetresgene autoleucel) are designed to target NY-ESO-1–expressing tumors through adoptive T-cell therapy, while approved products such as TECELRA (afamitresgene autoleucel) demonstrate the clinical progress achieved in this field. 
• These personalized therapies seek to deliver more durable responses, improve tumor-specific immune recognition, and enhance outcomes for patients with advanced or metastatic STS.
• In addition to conventional treatment strategies, novel therapeutic modalities, including intratumoral therapies, biomarker-guided precision oncology, and immune-based combination regimens, are gaining momentum across the STS pipeline. 
• These innovative approaches are being investigated primarily in advanced, metastatic, and recurrent disease settings, reflecting an increasing emphasis on personalized medicine, biomarker-driven patient selection, and enhanced antitumor immune responses. 
• Collectively, both marketed and emerging therapies are reshaping the future of STS management by offering more targeted and individualized treatment options.

Soft Tissue Sarcoma Competitive Landscape

Some of the soft tissue sarcoma drugs under development include TBI-1301 (mipetresgene autoleucel) (Takara Bio), INT230-6 (Intensity Therapeutics), ZEPZELCA (lurbinectedin) (PharmaMar/Jazz Pharmaceuticals), Pegargiminase (Polaris), Catequentinib Hydrochloride (AL3818) (Advenchen Laboratories), Fibromun (Philogen/Sun Pharma), Abemaciclib (VERZENIO) (Eli Lilly), Vusolimogene Oderparepvec (RP1) + Nivolumab (Replimune), Pembrolizumab (KEYTRUDA) + Eftilagimod Alpha (Immutep), Letetresgene autoleucel (US WorldMeds), Risvutatug rezetecan (GSK), Tigilanol Tiglate (QBiotics Group), and others.

Takara Bio’s TBI-1301 (mipetresgene autoleucel) is an investigational autologous T-cell receptor-engineered (TCR-T) cell therapy being developed by Takara Bio for the treatment of NY-ESO-1–positive malignancies, with a primary focus on synovial sarcoma. As of 2026, the therapy is undergoing evaluation in a Phase III confirmatory study involving patients with unresectable, advanced, or recurrent NY-ESO-1–positive synovial sarcoma. In May 2025, Japan’s Ministry of Health, Labour and Welfare (MHLW) granted mipetresgene autoleucel both Rare Disease and Sakigake designations, facilitating an expedited regulatory review pathway. Earlier, in May 2023, Takara Bio announced that clinical findings from the TBI-1301 program would be presented at the 2023 ASCO Annual Meeting in Chicago.

Intensity Therapeutics’ INT230-6 is an investigational intratumoral anticancer therapy from Intensity Therapeutics being studied for advanced solid tumors, including soft tissue sarcoma (STS). The treatment combines the chemotherapeutic agents cisplatin and vinblastine with the company’s proprietary DfuseRx platform, enabling enhanced drug dispersion throughout the tumor. This approach is designed to induce direct tumor cell destruction while simultaneously stimulating a systemic antitumor immune response.

PharmaMar/Jazz Pharmaceuticals’ ZEPZELCA (lurbinectedin) is a selective inhibitor of oncogenic transcription currently under investigation for advanced solid malignancies, including leiomyosarcoma. The therapy works by interfering with tumor transcriptional activity, suppressing cancer cell proliferation, triggering apoptosis, and modulating the tumor microenvironment to improve overall antitumor efficacy.

The anticipated launch of these emerging therapies are poised to transform the Soft Tissue Sarcoma market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the Soft Tissue Sarcoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about which pipeline drugs could transform soft tissue sarcoma treatment @ Soft Tissue Sarcoma Drugs

Recent Developments in the Soft Tissue Sarcoma Market

• In May 2026, Philogen scheduled parallel scientific advice with EMA and FDA to align on a new Phase III study of Fibromun in first-line STS; the new study is expected to start in 2026.
• In May 2026, PharmaMar reported completion of patient enrollment in the global Phase III SaLuDo trial evaluating ZEPZELCA (lurbinectedin) plus doxorubicin as first-line treatment for metastatic LMS.
• In April 2026, Immutep announced that the FDA had granted Orphan Drug Designation (ODD) to eftilagimod alfa (efti) for the treatment of Soft Tissue Sarcoma (STS), a rare malignancy associated with a substantial unmet medical need.
• In January 2026, Intensity Therapeutics announced that 21 patients had been enrolled in the Phase III INVINCIBLE-3 trial evaluating INT230-6 in metastatic STS before enrollment was temporarily paused due to funding constraints.
• In October 2025, PharmaMar received a USD 50 million milestone payment from Jazz Pharmaceuticals following the US FDA full approval of ZEPZELCA (lurbinectedin) under the company’s licensing agreement.

Soft Tissue Sarcoma Epidemiology Segmentation

The soft tissue sarcoma epidemiology section provides insights into the historical and current soft tissue sarcoma patient pool and forecasted trends for the leading markets. According to DelveInsight’s analysis, the US accounted for the highest number of STS incident cases in 2025, exceeding 13,500 cases, highlighting the substantial clinical burden in the region. The incidence is expected to continue increasing through 2036.

The soft tissue sarcoma treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

• Total Incident Cases of STS
• Gender-specific Incident Cases of STS
• Type-specific Incident Cases of STS
• Age-specific Incident Cases of STS
• Stage-specific Incident Cases of STS
• Extremity-specific Incident Cases of STS
• Total Treated Cases of STS

Scope of the Soft Tissue Sarcoma Market Report

• Soft Tissue Sarcoma Patient Population Forecast
• Soft Tissue Sarcoma Therapeutics Market Size
• Soft Tissue Sarcoma Pipeline Analysis
• Soft Tissue Sarcoma Market Size and Trends
• Soft Tissue Sarcoma Market Opportunity
• Soft Tissue Sarcoma Market Unmet Needs
• KOL’s Views on Soft Tissue Sarcoma
• Soft Tissue Sarcoma Market Access and Reimbursement

Table of Contents

Related Reports

Soft Tissue Sarcoma Clinical Trial Analysis

Soft Tissue Sarcoma Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key STS companies, including Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, and others.

Soft Tissue Sarcoma with Lung Metastases Market

Soft Tissue Sarcoma with Lung Metastases Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key STS-LM companies, including Moleculin, Immunophotonics, Philogen, Iovance Biotherapeutics, Chipscreen, Lyvgen, and others.

Osteosarcoma Market

Osteosarcoma Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key osteosarcoma companies including Takeda Pharmaceuticals, OS Therapies, Y-mAbs Therapeutics, AlaMab Therapeutics, CSPC Pharmaceutical, MedPacto, Hansoh Pharmaceutical, Takeda, Acrotech Biopharma, Bayer, Exelixis, Nektar Therapeutics, Eisai, GlaxoSmithKline/Novartis, Aadi Bioscience, Vaccinex, Inc., National Cancer Institute/Assaf-Harofeh Medical Center, Eleison Pharmaceuticals, Aurora Biopharma, BioAtla, Iovance Biotherapeutics, Isofol Medical AB, Bristol-Myers Squibb, Cellestia Biotech, and others.

Ewing Sarcoma Market

Ewing Sarcoma Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Ewing sarcoma companies including Salarius Pharmaceuticals, Jazz Pharmaceuticals, Pharmamar, Eli Lilly, Pfizer, Bioatla, Cellectar Biosciences, Sumitomo Pharma Oncology, Inhibrx, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/soft-tissue-sarcoma-market-set-for-significant-growth-at-a-cagr-of-7-9-during-the-forecast-period-20262036-driven-by-novel-therapies-and-expanding-treatment-landscape–delveinsight-302826017.html